Zymeworks (ZYME) Other Gross PP&E Adjustments (2021 - 2026)
Zymeworks recorded quarterly Other Gross PP&E Adjustments of -$14.0 million in Q1 2026, down 167.86% quarter-over-quarter from $20.7 million in Q4 2025, and up 16.19% year-over-year from -$12.1 million in Q1 2025.
Zymeworks' Other Gross PP&E Adjustments history runs 6 years deep, the most recent figure standing at -$14.0 million for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments rose 16.19% year-over-year to -$14.0 million; the TTM figure through Mar 2026 stood at -$14.0 million (up 16.19% YoY), while the FY2025 annual figure was $20.7 million, up 9.78% from the prior year.
- Other Gross PP&E Adjustments came in at -$14.0 million for Q1 2026 at Zymeworks, down from $20.7 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $22.8 million in Q4 2023 to a low of -$23.6 million in Q3 2022.
- A 5-year average of -$8.2 million and a median of -$16.7 million in 2025 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments jumped 52.94% in 2022 and declined 17.51% in 2024, its largest moves.
- Zymeworks' Other Gross PP&E Adjustments stood at $15.1 million in 2022, then jumped by 51.29% to $22.8 million in 2023, then slipped by 17.51% to $18.8 million in 2024, then gained by 9.78% to $20.7 million in 2025, then tumbled by 167.86% to -$14.0 million in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$14.0 million, $20.7 million, and -$16.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | -14.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.02 Mn |
| Mar 31, 2026 | -14.02 Mn |
| Dec 31, 2025 | 20.65 Mn |
| Dec 31, 2025 | 20.65 Mn |
| Sep 30, 2025 | -16.65 Mn |
| Sep 30, 2025 | -16.65 Mn |
| Jun 30, 2025 | -16.26 Mn |
| Jun 30, 2025 | -16.26 Mn |
| Mar 31, 2025 | -16.72 Mn |
| Mar 31, 2025 | -16.72 Mn |
| Dec 31, 2024 | 18.81 Mn |
| Dec 31, 2024 | 18.81 Mn |
| Sep 30, 2024 | -17.36 Mn |
| Sep 30, 2024 | -17.36 Mn |
| Jun 30, 2024 | -17.28 Mn |
| Jun 30, 2024 | -17.28 Mn |
| Mar 31, 2024 | -17.07 Mn |
| Mar 31, 2024 | -17.07 Mn |
| Dec 31, 2023 | 22.81 Mn |
| Dec 31, 2023 | 22.81 Mn |
| Sep 30, 2023 | -17.86 Mn |
| Sep 30, 2023 | -17.86 Mn |
| Jun 30, 2023 | -20.80 Mn |
| Jun 30, 2023 | -20.80 Mn |
| Mar 31, 2023 | -22.30 Mn |
| Mar 31, 2023 | -22.30 Mn |
| Dec 31, 2022 | 15.08 Mn |
| Dec 31, 2022 | 15.08 Mn |
| Sep 30, 2022 | -23.56 Mn |
| Sep 30, 2022 | -23.56 Mn |
| Dec 31, 2021 | 9.86 Mn |
| Dec 31, 2021 | 9.86 Mn |